Cognitive Disability and Quality of Life of Patients Suffering From Mu
Evaluation of Cognitive Disability and Quality of Life of Patients Suffering From Multiple Scleroses and Treat With Immunosuppressant
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Neuropsychological assessment
What it measured
Main measures
Evolution of the quality of life of patients diagnosed with relapsing MS and starting a treatment with immunosuppressant
on a 36 months period
Quality of life (reported by participants)
Other measures (11)
Analysis of variance for repeated measurement
15 to 30 days before the beginning of treatment, after 36 months
Selective Reminding Test (SRT)
15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Delayed recall of SRT
15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Visuo-spatial span
15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Digit span
15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Reverse span
15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Stroop test
15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
• Tiredness (EMIF SEP scale): Analysis of variance for repeated measurement
15 to 30 days before the beginning of treatment, 1st day of treatment, after 6,12,18 and 36 months
• Physical function (9HPT, 8 meter walk) : Analysis of variance for repeated measurement
15 to 30 days before the beginning of treatment, 1st day of treatment, after 6,12,18 and 36 months
Disability progressionWalking and mobilityDisability (EDSS) : Analysis of variance for repeated measurement
15 to 30 days before the beginning of treatment, 1st day of treatment, after 6,12,18 and 36 months
Disability progression
Who could take part
Relapsing MS · 18 and over
Show the full criteria
Inclusion criteria
* Clinical diagnosis of Relapsing MS since at least 6 months and less than 10 years * Neurological state stable since at least 1 month * Moderate Handicap (EDSS ≤ 5,5)
Exclusion criteria
* Secondary Progressive MS * Patient having an attack * Patient having experienced en MS relapse or recovered systemic corticosteroid in the previous 1 month * Depressive patient
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently. Immunosuppressants represent new treatments in Multiple Sclerosis (MS) but imply a lot of constraints. This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
Papers
Loading reviews and guidelines…
History
Started
Nov 2009
Main results due
Jan 2016
Finished
Jan 2016